动脉粥样硬化是一种慢性炎症和退行性过程,主要发生在大和中等大小的动脉,其形态学特征是动脉最内层的不对称局灶性增厚,内膜。这个过程是心血管疾病(CVDs)的基础,世界上最常见的死亡原因。一些研究表明,动脉粥样硬化与随后的COVID-19心血管疾病之间存在双向联系。这篇叙述性综述的目的是(1)概述指出COVID-19与动脉粥样硬化之间双向关系的最新研究;(2)总结心血管药物对COVID-19结局的影响。越来越多的证据表明,与没有心血管疾病的人相比,患有心血管疾病的人的COVID-19预后更差。此外,各种研究报道了COVID-19后新诊断的CVD患者的出现。最常见的CVD治疗可能会影响COVID-19的结果。因此,这篇综述简要讨论了它们在感染过程中的意义。更好地了解动脉粥样硬化之间的联系,CVD,和COVID-19可以主动识别危险因素,因此,制定策略以改善这些患者的预后。
Atherosclerosis is a chronic inflammatory and degenerative process that mainly occurs in large- and medium-sized arteries and is morphologically characterized by asymmetric focal thickenings of the innermost layer of the artery, the intima. This process is the basis of cardiovascular diseases (CVDs), the most common cause of death worldwide. Some studies suggest a bidirectional link between atherosclerosis and the consequent CVD with COVID-19. The aims of this narrative review are (1) to provide an overview of the most recent studies that point out a bidirectional relation between COVID-19 and atherosclerosis and (2) to summarize the impact of cardiovascular drugs on COVID-19 outcomes. A growing body of evidence shows that COVID-19 prognosis in individuals with CVD is worse compared with those without. Moreover, various studies have reported the emergence of newly diagnosed patients with CVD after COVID-19. The most common treatments for CVD may influence COVID-19 outcomes. Thus, their implication in the infection process is briefly discussed in this review. A better understanding of the link among atherosclerosis, CVD, and COVID-19 could proactively identify risk factors and, as a result, develop strategies to improve the prognosis for these patients.